All In Biotech

Drug Trial Radar · NCT04472429

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

308

Actual

Start

Nov 9, 2020

Primary completion

Apr 15, 2024

Study completion Sep 26, 2025

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jul 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.

Conditions

  • Squamous Cell Carcinoma of the Anal Canal

Interventions

  • carboplatinDrug

    carboplatin will be administered intravenous on Day 1 of each 28 day cycle

  • paclitaxelDrug

    paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle

  • retifanlimabDrug

    retifanlimab will be administered intravenous on Day 1 of each 28 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: up to 33.9 months

Locations

84 sites in 13 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Sansum Clinic

    Santa Barbara, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Ochsner Clinic

    New Orleans, Louisiana

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • Texas Oncology

    Austin, Texas

  • Baylor Scott and White Research Institute

    Dallas, Texas

  • Renovatio Clinical Consultants Llc

    The Woodlands, Texas

  • Texas Oncology-Wichita Falls Texoma Cancer Center

    Wichita Falls, Texas

  • Virginia Cancer Specialists, Pc

    Arlington, Virginia

  • Blue Ridge Cancer Care

    Roanoke, Virginia

  • Princess Alexandra Hospital Australia

    Woolloongabba, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Monash Medical Centre Clayton

    Clayton, Victoria, Australia

  • Zna Middelheim

    Antwerp, Belgium

  • Ulb Hospital Erasme

    Brussels, Belgium

  • Herlev Og Gentofte Hospital

    Herlev, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • Institut de Cancerologie de L Ouest - Site Paul Papin

    Angers, France

  • Chu Besancon Hospital Jean Minjoz

    Besançon, France

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • Chu Hopital de La Timone

    Marseille, France

  • Institut Du Cancer de Montpellier

    Montpellier, France

  • Centre Antoine Laccassagne

    Nice, France

  • Hospital Universitaire Pitie-Salpetriere

    Paris, France

  • Hospital de La Miletrie

    Poitiers, France

  • Chu de Rennes - Hospital Pontchaillou

    Rennes, France

  • Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume

    Rouen, France

  • Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau

    Saint-Herblain, France

  • Institut de Cancerologie de Strasbourg

    Strasbourg, France

  • Chu Toulouse Hopital Rangueil

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitatsklinikum Bonn Aoer

    Bonn, Germany

  • University Clinic Carl Gustav Carus Technical University Dresden

    Dresden, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    Milan, Italy

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.